Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Latest funding size
Time since last funding
|over 1 year|
|Sofinnova Ventures, Bay City Capital, Novartis Venture Fund, Pfizer Venture Investments, Rock Springs Capital, Tekla Capital Management, Johnson & Johnson Innovation, Novo A/S, RA Capital Healthcare, LSP Life Sciences Partners, Aglaia Oncology Fund, Bay City Capital, Novartis Venture Fund, Life Sciences Partners, Pfizer|